Leadership

Distinguished Academic Advisory Board

James O. Armitage, MD

Advisory Board Member

Dr. Armitage is globally recognized as a leading expert on non-Hodgkin lymphoma, and has played a critical role in advancing bone marrow transplantation. He developed and directed the bone marrow transplant programs at the University of Iowa and later at the University of Nebraska, where he also served as vice chair of Internal Medicine, chief of the Section of Oncology and Hematology, chair of the Department of Internal Medicine, and dean of the College of Medicine.

Stephen Caplan, MD

Advisory Board Member

Dr. Caplan is Associate Professor of Medicine, Director, Division of Hematology-Oncology, Sir Mortimer B. Davis-Jewish General Hospital, and Acting Director of the Division of Hematology at McGill University.

David Cohn, MD

Advisory Board Member

Dr. Cohn is Professor of Gynecologic Oncology, Director of the Division of Gynecologic Oncology, Director of Gynecologic Cancer Research, and Director of the Gynecologic Oncology Fellowship Program at The Ohio State University. Dr. Cohn’s interests include investigation of comparative effectiveness and cost-effective treatments for gynecologic cancers.

Deborah Dillon, MD

Advisory Board Member

Dr. Deborah Dillon is Assistant Professor of Pathology at Harvard Medical School. She received her MD at Yale Medical School and is board-certified in Anatomic and Molecular Genetic Pathology. She has worked as a breast and molecular pathologist for 20 years and has been on staff at Brigham and Women’s Hospital in Boston since 2004. As part of her clinical work in molecular diagnostics, she interprets both single-gene assays as well as high-throughput sequencing for solid tumors. In addition to clinical work in breast pathology and molecular diagnostics, Dr. Dillon’s particular area of interest is in biomarker development.

Dr. Dillon is a member of the College of American Pathologists Steering Committee for Biomarker Reporting and is a co-author of the CAP Templates for Reporting Results of Biomarker Testing in Breast Cancer and for Biomarker Reporting in Tumors of the Central Nervous System. She collaborates with basic scientists in the evaluation of new markers for breast cancer and new techniques for molecular analysis and works closely with breast oncologists in biomarker evaluation for clinical trials. She also serves as Director of the Dana Farber Harvard Cancer Center Breast Tissue Bank and Translational Research Laboratory and is a member of the pathology committee for the Alliance for Clinical Trials in Oncology.

Jay Harris, MD

Advisory Board Member

Dr. Harris is a professor of Radiation Oncology at Harvard Medical School. He is a highly-respected, international expert on breast cancer. His initial interest in breast cancer research was triggered because his maternal grandmother was diagnosed with the disease. Dr. Harris received his MD from Stanford University in 1970, where he also received an MS in statistics. He trained in radiation oncology at the Harvard Joint Center for Radiation Therapy, and joined the Dana-Farber Cancer Institute (DFCI) staff in 1977.

From 1985 to 1988, he was on the Editorial Board of JCO, and he served on the ASCO Board of Directors from 1997 to 2000. He also served as President and Chairman of the Board for the American Society for Therapeutic Radiology and Oncology and as a Trustee for the American Board of Radiology. From 1997 to 2015, Dr. Harris chaired the Department of Radiation Oncology at DFCI. In particular, he has been involved in the development and optimization of breast-conserving therapy for patients with invasive breast cancer and ductal carcinoma in situ. He has written over 240 peer-reviewed articles on breast malignancies. Also, he is a recipient of the 2007 ASTRO Gold Medal and the 2008 ASCO Gianni Bonadonna Breast Cancer Research Award.

Marc Lippman, MD

Advisory Board Member

Dr. Lippman is a pioneering breast cancer researcher. He is the Chairman of the Department of Medicine and Deputy Director of the Sylvester Comprehensive Cancer Center at the University of Miami. He is the former head of the Medical Breast Cancer section and Senior Investigator of the National Cancer Institute.

John Lister, MD

Advisory Board Member

Dr. Lister is Professor of Medicine at Temple University and Chief of Hematology and Oncology at the Western Pennsylvania Hospital. Dr. Lister has devoted his career to the study and treatment of hematologic malignancies.

John C. Ruckdeschel, MD

Advisory Board Member

Dr. Ruckdeschel is a leading authority on the diagnosis and management of thoracic malignancies with particular expertise in lung cancer. He received his BSc in biology from Rensselaer Polytechnic Institute and his MD from Albany Medical College in New York. He trained at Hopkins (Osler Intern), Beth Israel (Resident) and the National Cancer Institute (Fellow).

Chaim Shustik, MD

Advisory Board Member

Dr. Shustik is Professor of Medicine in the Division of Hematology/Oncology at McGill University. He is Chairman of the Myeloma Committee of the National Cancer Institute-Clinical Trials Group, and is the Principal Investigator of several clinical trials in multiple myeloma.